PUBLISHER: Renub Research | PRODUCT CODE: 1338991
PUBLISHER: Renub Research | PRODUCT CODE: 1338991
Global Vaccine Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis
Global Vaccine Market size is anticipated to reach US$ 92.32 Billion by 2028, according to Renub Research. There has been substantial progress in the availability of critical public health vaccinations during the previous two decades. New vaccinations have been developed and distributed globally, saving many lives and preventing illness. However, a thorough examination of the global vaccination business indicates significant impediments that continue to exist. Biological preparations known as vaccine give recipients active acquired immunity to infectious illnesses. They encourage the immune system to generate antibodies that will defend against upcoming infections. Vaccine prevent diseases like MMR, control contagion, eradicate smallpox, and save lives.
The use of vaccinations in the treatment and prevention of infectious illnesses has many benefits. Immunization prevents disease spread, protecting vaccinated and unvaccinated individuals. Studies confirm vaccine' reliability, safety, and efficacy. Immunization costs less than treating preventable diseases, making it a cost-effective public health strategy.
Global vaccine market is projected to grow at a CAGR of 8.64% between 2022 and 2028.
Vaccine remain the most effective method for preventing prevalent infectious diseases worldwide. In the United States, the incidence of influenza fluctuates annually, with approximately 38 million cases, 480,000 hospitalizations, and 34,000 deaths reported in 2022. Normally, 10% to 15% of the population is affected by the flu, but more severe seasons can lead to higher infection rates.
Vaccine technology has evolved, driven by the need for faster response and improved efficacy. Genetic engineering has enabled the development of new vaccine, including attenuated virus vaccine. Rapid detection and high concentration levels are achieved through advanced technologies. Innovation focuses on challenging targets, enhanced delivery systems, synthetic candidates, genomic analysis, antigen design, and nanoparticle delivery. These advancements revolutionize vaccine development for quicker deployment and increased effectiveness. However, vaccine development is a lengthy, complex, and expensive process lasting 10-15 years, influenced by variations in materials, equipment, and regulatory requirements, restricting market growth. As a result, the value of the global vaccine market was US$ 56.16 Billion in 2022.
Pneumococcal vaccine has a high share in the global vaccine market due to disease prevalence and emerging market demand
Vaccine market share shows that influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, Travel & Miscellaneous, HIB, Combos, Polio, Rotavirus, and Varicella segments make up the majority of the global vaccine market.
Pneumococcal illness is a deadly global hazard caused by Streptococcus pneumonia but can be prevented with vaccinations. Particularly pneumococcal conjugate vaccination (PCV13) for young children, they are commonly used. In areas with limited vaccine access, the demand for pneumococcal vaccine is rising. Their significant market share is driven by new discoveries, growing awareness, and improved accessibility.
United States is expected to continue to dominate the global vaccination industry in the years to come
By country, the global vaccine market is divided into the United States, Canada, Mexico, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World. The United States, with its robust pharmaceutical industry and leading vaccine manufacturers, including Pfizer, Merck, and Johnson & Johnson, holds a dominant position in the global vaccine market.
The country strong regulatory framework ensures the safety and efficacy of vaccine, fostering public trust and high coverage rates. The large and diverse population creates a substantial demand for vaccine, while supportive government policies provide financial backing for research, development, procurement, and distribution. The United States leads the world vaccination industry due to early investments in vaccine research, a strong public health system, and a supportive regulatory framework.
Influenza vaccine lead to vaccinated people share in the global vaccine market
Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, HIB, Combos, Polio, Rotavirus, and Varicella are among the vaccine that make up the majority of the world vaccine market by number of persons who have received them. Influenza is a deadly respiratory infection, but vaccine reduce illness risk by 40% to 60% globally, including in the US. Emerging markets exhibit a growing demand for influenza vaccine due to high prevalence and limited access to vaccine. These factors contribute to the expected high market share of influenza vaccine in the global vaccine market. The seasonal nature of influenza also aids in vaccination planning, government mandates increase vaccination rates, and increasing public awareness of the importance of influenza vaccination drives demand for these vaccine.
Combo vaccine, which combine multiple vaccine into a single shot. Combo vaccine offer the convenience of a single shot for patients and healthcare providers while providing effective protection against a wider range of pathogens. They are generally safe, with risks of side effects similar to separate vaccine. Combo vaccine can save on administration costs and the need for multiple doses, making them more cost-effective. The growth of combo vaccine is supported by government initiatives, rising awareness of vaccination benefits, and advancements in vaccine technology, leading to improved and more accessible options for protecting against multiple diseases.
Pediatric vaccine grow in the global vaccine market due to childhood diseases and their prevention effectiveness
Adult and Pediatric are the types constituting the global vaccine market. Pediatric vaccinations, including MMR, prevent serious illnesses and save lives. With recommendations from health agencies like the CDC in the US, these vaccine are extensively used throughout the world. In emerging areas where there is limited access to vaccine yet a high prevalence of children's diseases, there is an increasing demand for pediatric vaccine. New pediatric vaccine, growing vaccination awareness, and improved global immunization access contribute to higher childhood immunization rates, driving the market share of pediatric vaccine.
Global vaccine market is anticipated to continue to be dominated by Pediatric Vaccine
Adult and pediatric are the two categories in the global vaccine market. Worldwide, pediatric vaccine are crucial in preventing prevalent childhood diseases. For instance, measles, mumps, and rubella (MMR) can have severe consequences. Pediatric vaccine have high efficacy rates, such as the 97% effectiveness of the MMR vaccine. They are widely used, and experience growing demand, particularly in emerging markets with limited vaccine access. The development of new vaccine broadens protection against childhood diseases. Increasing awareness of vaccination importance and improved vaccine accessibility contribute to their global vaccine market features and trends growth. Governments often mandate pediatric vaccine due to the higher transmission risk and impact on children's health, further emphasizing their importance.
Key Players
GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited are some of the top companies competing in the global vaccine market. Market demand, R&D, patent protection, pricing, regulatory approvals, manufacturing capabilities, and global expansion drive competition among vaccine companies to meet needs, innovate, gain exclusivity, attract customers, ensure quality, and expand market reach.
In January 2022- In order to assess the safety, immunogenicity, and tolerability of a potential Omicron-based vaccination in adults between the ages of 18 and 55, Pfizer Inc. and BioNTech SE started a clinical trial.
Renub Research latest report "Global Vaccine Market, Vaccine Market Share (Influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, Travel & Miscellaneous, HIB, Combos, Polio, Rotavirus, and Varicella), Country (United States, Canada, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Mexico, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World), Vaccinated People (Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, HIB, Combos, Polio, Rotavirus, and Varicella), Categories (Adult, and pediatric), Companies (GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited)" provides a detailed analysis of Global Vaccine Market.
Vaccine Market Share - Global Vaccine Market has been covered from 14 viewpoints:
- 1. Influenza
- 2. HPV
- 3. Zoster
- 4. MMR
- 5. Pneumococcal
- 6. Meningococcal
- 7. Hepatitis
- 8. DTap/Tdap
- 9. Travel & Miscellaneous
- 10. HIB
- 11. Combos
- 12. Polio
- 13. Rotavirus
- 14. Varicella
Country - Global Vaccine Market has been covered from 21 viewpoints:
- 1. North America
- 1.1. United States
- 1.2. Canada
- 2. Europe
- 2.1. United Kingdom
- 2.2. Germany
- 2.3. France
- 2.4. Russia
- 2.5. Italy
- 2.6. Spain
- 2.7. Switzerland
- 3. Asia Pacific
- 3.1. India
- 3.2. China
- 3.3. Japan
- 3.4. Australia
- 3.5. South Korea
- 4. Latin America
- 4.1. Mexico
- 4.2. Brazil
- 4.3. Argentina
- 5. Middle East & Africa
- 5.1. Saudi Arabia
- 5.2. UAE
- 5.3. South Africa
- 6. Rest of the World
Vaccinated People - Global Vaccine Market has been covered from 13 viewpoints:
- 1. Influenza
- 2. Cervical Cancer
- 3. Zoster
- 4. MMR
- 5. Pneumococcal
- 6. Meningococcal
- 7. Hepatitis
- 8. DTap/Tdap
- 9. HIB
- 10. Combos
- 11. Polio
- 12. Rotavirus
- 13. Varicella
Category - Global Vaccine Market has been covered from 2 viewpoints:
- 1. Adult
- 2. Pediatric
Company Insights:
- Oveview
- Recent Development and Initiatives
- Sales Analysis
Company Analysis:
- 1. GlaxoSmithKline plc
- 2. AstraZeneca plc
- 3. Sanofi Pasteur
- 4. Pfizer Inc.
- 5. CSL Limited
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
- 4.1 Growth Driver
- 4.2 Challenges
5. Global Vaccines Market
- 5.1 Adult Vaccines Market
- 5.2 Pediatric (Infant) Vaccines Market
6. Global Vaccinated People
- 6.1 Adult Vaccinated People
- 6.2 Pediatric (Infant) Vaccinated People
7. Share Analysis - Global Vaccines Market & People
- 7.1 Vaccine Market Share
- 7.2 By Country
- 7.3 Vaccinated People Share
8. Categories - Global Vaccines Market & People Share
- 8.1 Adult VsPediatric (Infant) Vaccines Market Share
- 8.2 Adult VsPediatric (Infant) Vaccines Number Share
9. Disease wise - Vaccines Market and Forecast
- 9.1 Influenza - Total Vaccines Market
- 9.1.1 Influenza - Adult Vaccines Market
- 9.1.2 Influenza - Pediatric (Infant) Vaccines Market
- 9.2 Cervical Cancer (HPV) - Vaccines Market
- 9.3 Zoster (Shingles) - Vaccines Market
- 9.4 MMR (Measles, Mumps, and Rubella Vaccine) - Total Vaccines Market
- 9.4.1 MMR - Adult Vaccines Market
- 9.4.2 MMR - Pediatric (Infant) Vaccines Market
- 9.5 Pneumococcal - Total Vaccines Market
- 9.5.1 Pneumococcal - Adult Vaccines Market
- 9.5.2 Pneumococcal - Pediatric (Infant) Vaccines Market
- 9.6 Meningococcal - Total Vaccines Market
- 9.6.1 Meningococcal - Adult Vaccines Market
- 9.6.2 Meningococcal - Pediatric (Infant) Vaccines Market
- 9.7 Hepatitis - Total Vaccines Market
- 9.7.1 Hepatitis - Adult Vaccines Market
- 9.7.2 Hepatitis - Pediatric (Infant) Vaccines Market
- 9.8 TdaP and DTaP - Total Vaccines Market
- 9.8.1 TdaP - Adult Vaccines Market
- 9.8.2 DTaP - Pediatric (Infant) Vaccines Market
- 9.9 Travel and Miscellaneous - Vaccines Market
- 9.10 HaemophilusInfluenzae Type B (HIB) - Vaccines Market
- 9.11 Combos (Combination) - Vaccines Market
- 9.12 Polio - Vaccines Market
- 9.13 Rotavirus - Vaccines Market
- 9.14 Varicella - Vaccines Market
- 9.14.1 Varicella - Adult Vaccines Market
- 9.14.2 Varicella - Pediatric (Infant) Vaccines Market
10. Disease wise - Numbers of Vaccinated People & Forecast
- 10.1 Influenza - Total Number of Vaccinated People
- 10.1.1 Influenza - Number of Vaccinated Adults
- 10.1.2 Influenza - Number of Vaccinated Infants
- 10.2 Cervical Cancer (HPV) - Number of Vaccinated People
- 10.3 Zoster (Shingles) - Number of Vaccinated People
- 10.4 MMR - Total Number of Vaccinated People
- 10.4.1 MMR - Number of Vaccinated Adults
- 10.4.2 MMR - Number of Vaccinated Infants (Pediatric)
- 10.5 Pneumococcal - Total Number of Vaccinated People
- 10.5.1 Pneumococcal - Number of Vaccinated Adults
- 10.5.2 Pneumococcal - Number of Vaccinated Infants
- 10.6 Meningococcal - Total Number of Vaccinated People
- 10.6.1 Meningococcal - Number of Vaccinated Adults
- 10.6.2 Meningococcal - Number of Vaccinated Infants
- 10.7 Hepatitis - Total Number of Vaccinated People
- 10.7.1 Hepatitis - Number of Vaccinated Adults
- 10.7.2 Hepatitis - Number of Vaccinated Infants
- 10.8 TdaP and DTaP - Total Number of Vaccinated People
- 10.8.1 TdaP - Number of Vaccinated Adults
- 10.8.2 DTaP - Number of Vaccinated Infants
- 10.9 Hib (HaemophilusInfluenzae Type B) - Number of Vaaccinated Infants
- 10.10 Combos (Combination Vaccines) - Number of Vaccinated Infants
- 10.11 Polio - Number of Infants Immunized and Forecast
- 10.12 Rotavirus - Number of Vaccinated Infants
- 10.13 Varicella - Total Number of Vaccinated People
- 10.13.1 Varicella - Number of Vaccinated Adults
- 10.13.2 Varicella - Number of Vaccinated Infants
11. Country - Global Vaccine Market
- 11.1 North America
- 11.1.1 United States
- 11.1.2 Canada
- 11.2 Europe
- 11.2.1 United Kingdom
- 11.2.2 Germany
- 11.2.3 France
- 11.2.4 Russia
- 11.2.5 Italy
- 11.2.6 Spain
- 11.2.7 Switzerland
- 11.3 Asia Pacific
- 11.3.1 India
- 11.3.2 China
- 11.3.3 Japan
- 11.3.4 Australia
- 11.3.5 South Korea
- 11.4 Latin America
- 11.4.1 Mexico
- 11.4.2 Brazil
- 11.4.3 Argentina
- 11.5 Middle East & Africa
- 11.5.1 Saudi Arabia
- 11.5.2 UAE
- 11.5.3 South Africa
- 11.6 Rest of the World
12. Porter's Five Forces
- 12.1 Bargaining Power of Buyers
- 12.2 Bargaining Power of Suppliers
- 12.3 Degree of Competition
- 12.4 Threat of New Entrants
- 12.5 Threat of Substitutes
13. SWOT Analysis
- 13.1 Strengths
- 13.2 Weaknesses
- 13.3 Opportunities
- 13.4 Threats
14. Vaccines Key Players Sales
- 14.1 GlaxoSmithKline plc.
- 14.1.1 Overview
- 14.1.2 Recent Development
- 14.1.3 Financial Insights
- 14.2 Astrazeneca plc
- 14.2.1 Overview
- 14.2.2 Recent Development
- 14.2.3 Financial Insights
- 14.3 Sanofi Pasteur
- 14.3.1 Overview
- 14.3.2 Recent Development
- 14.3.3 Financial Insights
- 14.4 Pfizer, Inc.
- 14.4.1 Overview
- 14.4.2 Recent Development
- 14.4.3 Financial Insights
- 14.5 CSL Limited sales
- 14.5.1 Overview
- 14.5.2 Recent Development
- 14.5.3 Financial Insights
List of Figures
- Figure-01: Global - Vaccines Market (Million US$), 2018 - 2022
- Figure-02: Global - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-03: Global - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-04: Global - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-05: Global - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-06: Global - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-07: Global - Vaccinated People Volume (Million), 2018 - 2022
- Figure-08: Global - Forecast for Vaccinated People Volume (Million), 2023 - 2028
- Figure-09: Global - Adult Vaccinated People Volume (Million), 2018 - 2022
- Figure-10: Global - Forecast for Adult Vaccinated People Volume (Million), 2023 - 2028
- Figure-11: Global - Pediatric (Infant) Vaccinated People Volume (Million), 2018 - 2022
- Figure-12: Global - Forecast for Pediatric (Infant) Vaccinated People Volume (Million), 2023 - 2028
- Figure-13: Influenza - Total Vaccines Market (Million US$), 2018 - 2022
- Figure-14: Influenza - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
- Figure-15: Influenza - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-16: Influenza - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-17: Influenza - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-18: Influenza - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-19: Cervical Cancer (HPV) - Vaccines Market (Million US$), 2018 - 2022
- Figure-20: Cervical Cancer (HPV) - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-21: Zoster (Shingles) - Vaccines Market (Million US$), 2018 - 2022
- Figure-22: Zoster (Shingles) - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-23: MMR - Total Vaccines Market (Million US$), 2018 - 2022
- Figure-24: MMR - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
- Figure-25: MMR - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-26: MMR - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-27: MMR - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-28: MMR - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-29: Pneumococcal - Total Vaccines Market (Million US$), 2018 - 2022
- Figure-30: Pneumococcal - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
- Figure-31: Pneumococcal - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-32: Pneumococcal - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-33: Pneumococcal - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-34: Pneumococcal - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-35: Meningococcal - Total Vaccines Market (Million US$), 2018 - 2022
- Figure-36: Meningococcal - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
- Figure-37: Meningococcal - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-38: Meningococcal - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-39: Meningococcal - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-40: Meningococcal - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-41: Hepatitis - Total Vaccines Market (Million US$), 2018 - 2022
- Figure-42: Hepatitis - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
- Figure-43: Hepatitis - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-44: Hepatitis - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-45: Hepatitis - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-46: Hepatitis - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-47: TdaP and DTaP - Total Vaccines Market (Million US$), 2018 - 2022
- Figure-48: TdaP and DTaP - Forecast for Total Vaccines Market (Million US$), 2023 - 2028
- Figure-49: TdaP - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-50: TdaP - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-51: DTaP - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-52: DTaP - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-53: Travel and Miscellaneous - Vaccines Market (Million US$), 2018 - 2022
- Figure-54: Travel and Miscellaneous - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-55: Haemophilus Influenzae Type B (HIB) - Vaccines Market (Million US$), 2018 - 2022
- Figure-56: Haemophilus Influenzae Type B (HIB) - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-57: Combos (Combination) - Vaccines Market (Million US$), 2018 - 2022
- Figure-58: Combos (Combination) - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-59: Polio - Vaccines Market (Million US$), 2018 - 2022
- Figure-60: Polio - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-61: Rotavirus - Vaccines Market (Million US$), 2018 - 2022
- Figure-62: Rotavirus - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-63: Varicella - Vaccines Market (Million US$), 2018 - 2022
- Figure-64: Varicella - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-65: Varicella - Adult Vaccines Market (Million US$), 2018 - 2022
- Figure-66: Varicella - Forecast for Adult Vaccines Market (Million US$), 2023 - 2028
- Figure-67: Varicella - Pediatric (Infant) Vaccines Market (Million US$), 2018 - 2022
- Figure-68: Varicella - Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 - 2028
- Figure-69: Influenza - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-70: Influenza - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-71: Influenza - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-72: Influenza - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-73: Influenza - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-74: Influenza - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-75: Cervical Cancer (HPV) - Number of Vaccinated People (Million), 2018 - 2022
- Figure-76: Cervical Cancer (HPV) - Forecast for Number of Vaccinated People (Million), 2023 - 2028
- Figure-77: Zoster (Shingles) - Number of Vaccinated People (Million), 2018 - 2022
- Figure-78: Zoster (Shingles) - Forecast for Number of Vaccinated People (Million), 2023 - 2028
- Figure-79: MMR - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-80: MMR - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-81: MMR - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-82: MMR - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-83: MMR - Number of Vaccinated Infants (Pediatric) (Million), 2018 - 2022
- Figure-84: MMR - Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2023 - 2028
- Figure-85: Pneumococcal - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-86: Pneumococcal - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-87: Pneumococcal - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-88: Pneumococcal - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-89: Pneumococcal - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-90: Pneumococcal - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-91: Meningococcal - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-92: Meningococcal - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-93: Meningococcal - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-94: Meningococcal - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-95: Meningococcal - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-96: Meningococcal - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-97: Hepatitis - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-98: Hepatitis - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-99: Hepatitis - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-100: Hepatitis - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-101: Hepatitis - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-102: Hepatitis - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-103: TdaP and DTaP - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-104: TdaP and DTaP - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-105: TdaP - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-106: TdaP - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-107: DTaP - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-108: DTaP - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-109: Hib (Haemophilus Influenzae Type B) - Number of Vaaccinated Infants (Million), 2018 - 2022
- Figure-110: Hib (Haemophilus Influenzae Type B) - Forecast for Number of Vaaccinated Infants (Million), 2023 - 2028
- Figure-111: Combos (Combination Vaccines) - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-112: Combos (Combination Vaccines) - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-113: Polio - Number of Infants Immunized and Forecast (Million), 2018 - 2022
- Figure-114: Polio - Forecast for Number of Infants Immunized and Forecast (Million), 2023 - 2028
- Figure-115: Rotavirus - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-116: Rotavirus - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-117: Varicella - Total Number of Vaccinated People (Million), 2018 - 2022
- Figure-118: Varicella - Forecast for Total Number of Vaccinated People (Million), 2023 - 2028
- Figure-119: Varicella - Number of Vaccinated Adults (Million), 2018 - 2022
- Figure-120: Varicella - Forecast for Number of Vaccinated Adults (Million), 2023 - 2028
- Figure-121: Varicella - Number of Vaccinated Infants (Million), 2018 - 2022
- Figure-122: Varicella - Forecast for Number of Vaccinated Infants (Million), 2023 - 2028
- Figure-123: United States - Vaccines Market (Million US$), 2018 - 2022
- Figure-124: United States - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-125: Canada - Vaccines Market (Million US$), 2018 - 2022
- Figure-126: Canada - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-127: United Kingdom - Vaccines Market (Million US$), 2018 - 2022
- Figure-128: United Kingdom - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-129: Germany - Vaccines Market (Million US$), 2018 - 2022
- Figure-130: Germany - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-131: France - Vaccines Market (Million US$), 2018 - 2022
- Figure-132: France - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-133: Russia - Vaccines Market (Million US$), 2018 - 2022
- Figure-134: Russia - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-135: Italy - Vaccines Market (Million US$), 2018 - 2022
- Figure-136: Italy - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-137: Spain - Vaccines Market (Million US$), 2018 - 2022
- Figure-138: Spain - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-139: Switzerland - Vaccines Market (Million US$), 2018 - 2022
- Figure-140: Switzerland - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-141: India - Vaccines Market (Million US$), 2018 - 2022
- Figure-142: India - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-143: China - Vaccines Market (Million US$), 2018 - 2022
- Figure-144: China - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-145: Japan - Vaccines Market (Million US$), 2018 - 2022
- Figure-146: Japan - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-147: Australia - Vaccines Market (Million US$), 2018 - 2022
- Figure-148: Australia - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-149: South Korea - Vaccines Market (Million US$), 2018 - 2022
- Figure-150: South Korea - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-151: Mexico - Vaccines Market (Million US$), 2018 - 2022
- Figure-152: Mexico - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-153: Brazil - Vaccines Market (Million US$), 2018 - 2022
- Figure-154: Brazil - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-155: Argentina - Vaccines Market (Million US$), 2018 - 2022
- Figure-156: Argentina - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-157: Saudi Arabia - Vaccines Market (Million US$), 2018 - 2022
- Figure-158: Saudi Arabia - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-159: UAE - Vaccines Market (Million US$), 2018 - 2022
- Figure-160: UAE - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-161: South Africa - Vaccines Market (Million US$), 2018 - 2022
- Figure-162: South Africa - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-163: Rest of the World - Vaccines Market (Million US$), 2018 - 2022
- Figure-164: Rest of the World - Forecast for Vaccines Market (Million US$), 2023 - 2028
- Figure-165: GlaxoSmithKline, plc. - Global Revenue (Billion US$), 2018 - 2022
- Figure-166: GlaxoSmithKline, plc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
- Figure-167: Astrazeneca plc - Global Revenue (Million US$), 2018 - 2022
- Figure-168: Astrazeneca plc - Forecast for Global Revenue (Million US$), 2023 - 2028
- Figure-169: Sanofi Pasteur - Global Revenue (Billion US$), 2018 - 2022
- Figure-170: Sanofi Pasteur - Forecast for Global Revenue (Billion US$), 2023 - 2028
- Figure-171: Pfizer, Inc. - Global Revenue (Billion US$), 2018 - 2022
- Figure-172: Pfizer, Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
- Figure-173: CSL Limited - Global Revenue (Billion US$), 2018 - 2022
- Figure-174: CSL Limited - Forecast for Global Revenue (Billion US$), 2023 - 2028
List of Tables
- Table-01: Global - Vaccines Market Share (Percent), 2018 - 2022
- Table-02: Global - Forecast for Vaccines Market Share (Percent), 2023 - 2028
- Table-03: Global - Vaccines Market Share by Country (Percent), 2018 - 2022
- Table-04: Global - Forecast for Vaccines Market Share by Country (Percent), 2023 - 2028
- Table-05: Global - Vaccinated People Share (Percent), 2018 - 2022
- Table-06: Global - Forecast for Vaccinated People Share (Percent), 2023 - 2028
- Table-07: Global - Adult Vs Pediatric (Infant) Vaccines Market Share (Percent), 2018 - 2022
- Table-08: Global - Forecast for Adult Vs Pediatric (Infant) Vaccines Market Share (Percent), 2023 - 2028
- Table-09: Global - Adult Vs Pediatric (Infant) Vaccines Number Share (Percent), 2018 - 2022
- Table-10: Global - Forecast for Adult Vs Pediatric (Infant) Vaccines Number Share (Percent), 2023 - 2028
